CD93 and acute myeloid leukemia: Other surface targets that have been considered in the context of AML and antibody‐mediated elimination of LSC include CD44, CD45, CD47, CD93, CD96, CD157, CD330f, and CLL‐1.8, 30, 31, 32, 33, 34, 38, 43, 68, 69, 70